

Clinical trials of albiglutide weekly

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
albiglutide weekly vs placebo (add on MET)			
Rosenstock (30 mg weekly) , 2009 [NCT00518115] n=31/52 follow-up: 16 weeks	albiglutide 30mg weekly versus placebo	patients with type 2 diabetes inadequately controlled with diet and exercise or metformin monotherapy	Parallel groups double-blind US, Mexico, Chile, Dominical republic

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>

References

Rosenstock (30 mg weekly), 2009:

Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, , Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6. [19592625] [10.2337/dc09-0366](https://doi.org/10.2337/dc09-0366)

Entry terms: albiglutide, albiglutide,